Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results

Ítems similars

• Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
  per: Zweifel, M, et al.
  Publicat: (2011)
• A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
  per: Rustin, G, et al.
  Publicat: (2010)
• A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors
  per: Nathan, P, et al.
  Publicat: (2008)
• Phase IB dose-escalation and expansion study of AKT kinase inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer
  per: Blagden, S, et al.
  Publicat: (2018)
• Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
  per: Nathan, P, et al.
  Publicat: (2012)